Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition

04 Sep 2023

Boehringer Ingelheim's head of innovation Michel Pairet tells Scrip that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.

Boehringer Ingelheim headquarters in Ingelheim, Germany — BI's R&D strategy centers on novel targets and breakthrough therapies for unmet needs • Source: Boehringer Ingelheim (dieth+schröder-fotografie)

Like many of its large pharma peers, Boehringer Ingelheim likes to talk about its lofty research and development goals and sourcing external innovation to stay on the cutting edge of therapeutic modalities, target discovery and validation, and ways to hit those targets. The German firm sets high standards for best- and/or first-in-class pipeline assets and breakthrough therapy designations.

But as a privately held and family-owned pharmaceutical company, BI has advantages over its peers in terms of being able...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

25 Jul 2025

• By Jessica Merrill

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

24 Jul 2025

• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

24 Jul 2025

• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.